These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 17390024)
1. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner. Richard CL; Blay J Int J Oncol; 2007 May; 30(5):1215-22. PubMed ID: 17390024 [TBL] [Abstract][Full Text] [Related]
2. 15-Deoxy-delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways. Richard CL; Lowthers EL; Blay J Exp Cell Res; 2007 Oct; 313(16):3446-58. PubMed ID: 17707368 [TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. Lin MS; Chen WC; Bai X; Wang YD J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820 [TBL] [Abstract][Full Text] [Related]
4. Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression. Rovito D; Gionfriddo G; Barone I; Giordano C; Grande F; De Amicis F; Lanzino M; Catalano S; Andò S; Bonofiglio D Oncotarget; 2016 Oct; 7(40):65109-65124. PubMed ID: 27556298 [TBL] [Abstract][Full Text] [Related]
5. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896 [TBL] [Abstract][Full Text] [Related]
6. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion. Yang DR; Lin SJ; Ding XF; Miyamoto H; Messing E; Li LQ; Wang N; Chang C Urology; 2013 May; 81(5):1109.e1-6. PubMed ID: 23522297 [TBL] [Abstract][Full Text] [Related]
7. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131 [TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333 [TBL] [Abstract][Full Text] [Related]
9. MCC-555-induced NAG-1 expression is mediated in part by KLF4. Cekanova M; Lee SH; McEntee MF; Baek SJ Eur J Pharmacol; 2010 Jul; 637(1-3):30-7. PubMed ID: 20385121 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells. Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578 [TBL] [Abstract][Full Text] [Related]
12. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism. Akinyeke TO; Stewart LV Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782 [TBL] [Abstract][Full Text] [Related]
13. Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. Yaacob NS; Darus HM; Norazmi MN Exp Toxicol Pathol; 2008 Sep; 60(6):505-12. PubMed ID: 18579355 [TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Yang CC; Ku CY; Wei S; Shiau CW; Chen CS; Pinzone JJ; Ringel MD; Chen CS Mol Pharmacol; 2006 May; 69(5):1564-70. PubMed ID: 16452400 [TBL] [Abstract][Full Text] [Related]
15. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Shimazaki N; Togashi N; Hanai M; Isoyama T; Wada K; Fujita T; Fujiwara K; Kurakata S Eur J Cancer; 2008 Aug; 44(12):1734-43. PubMed ID: 18511262 [TBL] [Abstract][Full Text] [Related]
17. Regulation of cigarette smoke-induced toll-like receptor 4 expression by peroxisome proliferator-activated receptor-gamma agonists in bronchial epithelial cells. Yin Y; Hou G; Li ER; Wang QY; Kang J Respirology; 2013 Nov; 18 Suppl 3():30-9. PubMed ID: 24188201 [TBL] [Abstract][Full Text] [Related]
18. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570 [TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Huang JW; Shiau CW; Yang YT; Kulp SK; Chen KF; Brueggemeier RW; Shapiro CL; Chen CS Mol Pharmacol; 2005 Apr; 67(4):1342-8. PubMed ID: 15653552 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel. Pavlov TS; Levchenko V; Karpushev AV; Vandewalle A; Staruschenko A Mol Pharmacol; 2009 Dec; 76(6):1333-40. PubMed ID: 19752200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]